AAAAAA

   
Results: 1-25 | 26-39
Results: 1-25/39
IMMUNOLOGICAL RESPONSE TO THE DUAL MURINE ANTI-ID VACCINE MELIMMUNE-1AND MELIMMUNE-2 IN PATIENTS WITH HIGH-RISK MELANOMA WITHOUT EVIDENCE OF SYSTEMIC-DISEASE
Authors: SALEH MN LALISAN DY PRIDE MW SOLINGER A MAYO MS LOBUGLIO AF MURRAY JL
Citation: Mn. Saleh et al., IMMUNOLOGICAL RESPONSE TO THE DUAL MURINE ANTI-ID VACCINE MELIMMUNE-1AND MELIMMUNE-2 IN PATIENTS WITH HIGH-RISK MELANOMA WITHOUT EVIDENCE OF SYSTEMIC-DISEASE, Journal of immunotherapy, 21(5), 1998, pp. 379-388
PHASE-I STUDY OF DIFFERENT SCHEDULES OF THE HUMANIZED ANTI-EGP40 MOAB3622W94 IN PATIENTS WITH ANTIGEN-EXPRESSING EPITHELIAL TUMORS
Authors: SALEH MN LOBUGLIO AF POSEY JA OSTROFF JB KHOR SP THURMOND LM BIGLEY JW
Citation: Mn. Saleh et al., PHASE-I STUDY OF DIFFERENT SCHEDULES OF THE HUMANIZED ANTI-EGP40 MOAB3622W94 IN PATIENTS WITH ANTIGEN-EXPRESSING EPITHELIAL TUMORS, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 13(1), 1998, pp. 8-8
POLYNUCLEOTIDE IMMUNIZATION OF NONHUMAN-PRIMATES AGAINST CARCINOEMBRYONIC ANTIGEN
Authors: CONRY RM WHITE SA FULTZ PN KHAZAELI MB STRONG TV ALLEN KO BARLOW DL MOORE SE COAN PN DAVIS I CURIEL DT LOBUGLIO AF
Citation: Rm. Conry et al., POLYNUCLEOTIDE IMMUNIZATION OF NONHUMAN-PRIMATES AGAINST CARCINOEMBRYONIC ANTIGEN, Clinical cancer research, 4(11), 1998, pp. 2903-2912
CHIMERIC ANTIBODIES WITH SPECIFICITY FOR TUMOR-ANTIGENS - DEMONSTRATION OF IN-SITU LOCALIZATION TO TUMORS AFTER ANTIBODY THERAPY
Authors: SALEH MN TILDEN AB MEREDITH RF LOBUGLIO AF GRIZZLE WE
Citation: Mn. Saleh et al., CHIMERIC ANTIBODIES WITH SPECIFICITY FOR TUMOR-ANTIGENS - DEMONSTRATION OF IN-SITU LOCALIZATION TO TUMORS AFTER ANTIBODY THERAPY, Biotechnic & histochemistry, 73(4), 1998, pp. 186-197
EFFECTS OF A NOVEL PURINE NUCLEOSIDE PHOSPHORYLASE INHIBITOR, BCX-34,ON ACTIVATION AND PROLIFERATION OF NORMAL HUMAN LYMPHOID-CELLS
Authors: CONRY RM BANTIA S TURNER HS BARLOW DL ALLEN KO LOBUGLIO AF MONTGOMERY JA WALSH GM
Citation: Rm. Conry et al., EFFECTS OF A NOVEL PURINE NUCLEOSIDE PHOSPHORYLASE INHIBITOR, BCX-34,ON ACTIVATION AND PROLIFERATION OF NORMAL HUMAN LYMPHOID-CELLS, Immunopharmacology, 40(1), 1998, pp. 1-9
CORRELATION OF TOXICITY WITH TREATMENT PARAMETERS FOR I-131 CC49 RADIOIMMUNOTHERAPY IN 3 PHASE-II CLINICAL-TRIALS
Authors: LIU TP MEREDITH RF SALEH MN WHEELER RH KHAZAELI MB PLOTT WE SCHLOM J LOBUGLIO AF
Citation: Tp. Liu et al., CORRELATION OF TOXICITY WITH TREATMENT PARAMETERS FOR I-131 CC49 RADIOIMMUNOTHERAPY IN 3 PHASE-II CLINICAL-TRIALS, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 12(2), 1997, pp. 79-87
PHASE-I TRIAL OF POLYNUCLEOTIDE IMMUNIZATION TO CARCINOEMBRYONIC ANTIGEN IN PATIENTS WITH METASTATIC COLORECTAL-CANCER
Authors: CONRY RM STRONG TV WHITE SA KHAZAELI MB LOBUGLIO AF CURIEL DT
Citation: Rm. Conry et al., PHASE-I TRIAL OF POLYNUCLEOTIDE IMMUNIZATION TO CARCINOEMBRYONIC ANTIGEN IN PATIENTS WITH METASTATIC COLORECTAL-CANCER, Cancer gene therapy, 4(6), 1997, pp. 126-126
RADIATION ABSORBED DOSE ESTIMATES TO TUMORS ORGANS FROM INTRA-PERITONEAL ADMINISTERED LU-177 CC49 IN OVARIAN-CANCER PATIENTS
Authors: MACEY DJ MEREDITH RF PLOTT WE BREZOVICH IA ELLIOT G KHAZELLI MB LOBUGLIO AF
Citation: Dj. Macey et al., RADIATION ABSORBED DOSE ESTIMATES TO TUMORS ORGANS FROM INTRA-PERITONEAL ADMINISTERED LU-177 CC49 IN OVARIAN-CANCER PATIENTS, The Journal of nuclear medicine, 38(5), 1997, pp. 962-962
INTRAPERITONEAL RADIOIMMUNOTHERAPY OF OVARIAN-CANCER WITH LU-177-CC49- A PHASE I II STUDY/
Authors: ALVAREZ RD PARTRIDGE EE KHAZAELI MB PLOTT G AUSTIN M KILGORE L RUSSELL CD LIU TP GRIZZLE WE SCHLOM J LOBUGLIO AF MEREDITH RF
Citation: Rd. Alvarez et al., INTRAPERITONEAL RADIOIMMUNOTHERAPY OF OVARIAN-CANCER WITH LU-177-CC49- A PHASE I II STUDY/, Gynecologic oncology, 65(1), 1997, pp. 94-101
SIMULATION OF TUMOR-SPECIFIC DELIVERY OF RADIOLIGAND COMPARISON OF ONE-STEP, 2-STEP, AND GENETIC TRANSDUCTION SYSTEMS
Authors: LIU TP BUCHSBAUM DJ CURIEL DT KHAZAELI MB MEREDITH RF LOBUGLIO AF
Citation: Tp. Liu et al., SIMULATION OF TUMOR-SPECIFIC DELIVERY OF RADIOLIGAND COMPARISON OF ONE-STEP, 2-STEP, AND GENETIC TRANSDUCTION SYSTEMS, JOURNAL OF MOLECULAR MODELING, 2(12), 1996, pp. 467-477
PHASE-II STUDY OF DUAL I-131-LABELED MONOCLONAL-ANTIBODY THERAPY WITHINTERFERON IN PATIENTS WITH METASTATIC COLORECTAL-CANCER
Authors: MEREDITH RF KHAZAELI MB PLOTT WE GRIZZLE WE LIU TP SCHLOM J RUSSELL CD WHEELER RH LOBUGLIO AF
Citation: Rf. Meredith et al., PHASE-II STUDY OF DUAL I-131-LABELED MONOCLONAL-ANTIBODY THERAPY WITHINTERFERON IN PATIENTS WITH METASTATIC COLORECTAL-CANCER, Clinical cancer research, 2(11), 1996, pp. 1811-1818
PHASE IA TRIAL OF A POLYNUCLEOTIDE ANTITUMOR IMMUNIZATION TO HUMAN CARCINOEMBRYONIC ANTIGEN IN PATIENTS WITH METASTATIC COLORECTAL-CANCER
Authors: CONRY RM LOBUGLIO AF CURIEL DT
Citation: Rm. Conry et al., PHASE IA TRIAL OF A POLYNUCLEOTIDE ANTITUMOR IMMUNIZATION TO HUMAN CARCINOEMBRYONIC ANTIGEN IN PATIENTS WITH METASTATIC COLORECTAL-CANCER, Human gene therapy, 7(6), 1996, pp. 755-772
SELECTED STRATEGIES TO AUGMENT POLYNUCLEOTIDE IMMUNIZATION
Authors: CONRY RM WIDERA G LOBUGLIO AF FULLER JT MOORE SE BARLOW DL TURNER J CURIEL DT
Citation: Rm. Conry et al., SELECTED STRATEGIES TO AUGMENT POLYNUCLEOTIDE IMMUNIZATION, Gene therapy, 3(1), 1996, pp. 67-74
INTRAPERITONEAL RADIOIMMUNOTHERAPY OF OVARIAN-CANCER WITH LUTETIUM-177-CC49
Authors: MEREDITH RF PARTRIDGE EE ALVAREZ RD KHAZAELI MB PLOTT G RUSSELL CD WHEELER RH LIU TP GRIZZLE WE SCHLOM J LOBUGLIO AF
Citation: Rf. Meredith et al., INTRAPERITONEAL RADIOIMMUNOTHERAPY OF OVARIAN-CANCER WITH LUTETIUM-177-CC49, The Journal of nuclear medicine, 37(9), 1996, pp. 1491-1496
POLYNUCLEOTIDE-MEDIATED IMMUNIZATION THERAPY OF CANCER
Authors: CONRY RM LOBUGLIO AF CURIEL DT
Citation: Rm. Conry et al., POLYNUCLEOTIDE-MEDIATED IMMUNIZATION THERAPY OF CANCER, Seminars in oncology, 23(1), 1996, pp. 135-147
IDEC-C2B8 CHOP CHEMOIMMUNOTHERAPY IN PATIENTS WITH LOW-GRADE LYMPHOMA- CLINICAL AND BCL-2 (PCR) FINAL RESULTS/
Authors: CZUCZMAN M GRILLOLOPEZ AJ WHITE CA SALEH M GORDON L LOBUGLIO AF JONAS C DALLAIRE B VARNS C
Citation: M. Czuczman et al., IDEC-C2B8 CHOP CHEMOIMMUNOTHERAPY IN PATIENTS WITH LOW-GRADE LYMPHOMA- CLINICAL AND BCL-2 (PCR) FINAL RESULTS/, Blood, 88(10), 1996, pp. 1799-1799
PHASE-I TRIAL OF AN ANTI-CD19 DEGLYCOSYLATED RICIN-A CHAIN IMMUNOTOXIN IN NON-HODGKINS-LYMPHOMA - EFFECT OF AN INTENSIVE SCHEDULE OF ADMINISTRATION
Authors: CONRY RM KHAZAELI MB SALEH MN GHETIE V VITETTA ES LIU TP LOBUGLIO AF
Citation: Rm. Conry et al., PHASE-I TRIAL OF AN ANTI-CD19 DEGLYCOSYLATED RICIN-A CHAIN IMMUNOTOXIN IN NON-HODGKINS-LYMPHOMA - EFFECT OF AN INTENSIVE SCHEDULE OF ADMINISTRATION, Journal of immunotherapy with emphasis on tumor immunology, 18(4), 1995, pp. 231-241
A CARCINOEMBRYONIC ANTIGEN POLYNUCLEOTIDE VACCINE HAS IN-VIVO ANTITUMOR-ACTIVITY
Authors: CONRY RM LOBUGLIO AF LOECHEL F MOORE SE SUMEREL LA BARLOW DL CURIEL DT
Citation: Rm. Conry et al., A CARCINOEMBRYONIC ANTIGEN POLYNUCLEOTIDE VACCINE HAS IN-VIVO ANTITUMOR-ACTIVITY, Gene therapy, 2(1), 1995, pp. 59-65
A CARCINOEMBRYONIC ANTIGEN POLYNUCLEOTIDE VACCINE FOR HUMAN CLINICAL USE
Authors: CONRY RM LOBUGLIO AF LOECHEL F MOORE SE SUMEREL LA BARLOW DL PIKE J CURIEL DT
Citation: Rm. Conry et al., A CARCINOEMBRYONIC ANTIGEN POLYNUCLEOTIDE VACCINE FOR HUMAN CLINICAL USE, Cancer gene therapy, 2(1), 1995, pp. 33-38
A SINDBIS VIRUS MESSENGER-RNA POLYNUCLEOTIDE VECTOR ACHIEVES PROLONGED AND HIGH-LEVEL HETEROLOGOUS GENE-EXPRESSION IN-VIVO
Authors: JOHANNING FW CONRY RM LOBUGLIO AF WRIGHT M SUMEREL LA PIKE MJ CURIEL DT
Citation: Fw. Johanning et al., A SINDBIS VIRUS MESSENGER-RNA POLYNUCLEOTIDE VECTOR ACHIEVES PROLONGED AND HIGH-LEVEL HETEROLOGOUS GENE-EXPRESSION IN-VIVO, Nucleic acids research, 23(9), 1995, pp. 1495-1501
INITIAL CLINICAL-EVALUATION OF IODINE-125-LABELED CHIMERIC 17-1A FOR METASTATIC COLON-CANCER
Authors: MEREDITH RF KHAZAELI MB PLOTT WE SPENCER SA WHEELER RH BRADY LW WOO DV LOBUGLIO AF
Citation: Rf. Meredith et al., INITIAL CLINICAL-EVALUATION OF IODINE-125-LABELED CHIMERIC 17-1A FOR METASTATIC COLON-CANCER, The Journal of nuclear medicine, 36(12), 1995, pp. 2229-2233
CHARACTERIZATION OF A MESSENGER-RNA POLYNUCLEOTIDE VACCINE VECTOR
Authors: CONRY RM LOBUGLIO AF WRIGHT M SUMEREL L PIKE MJ FENG JN BENJAMIN R LU D CURIEL DT
Citation: Rm. Conry et al., CHARACTERIZATION OF A MESSENGER-RNA POLYNUCLEOTIDE VACCINE VECTOR, Cancer research, 55(7), 1995, pp. 1397-1400
PHASE-II TRIAL OF MURINE MONOCLONAL-ANTIBODY D612 COMBINED WITH RECOMBINANT HUMAN MONOCYTE COLONY-STIMULATING FACTOR (RHM-CSF) IN PATIENTS WITH METASTATIC GASTROINTESTINAL CANCER
Authors: SALEH MN KHAZAELI MB WHEELER RH BUCY RP LIU TP EVERSON MP MUNN DH SCHLOM J LOBUGLIO AF
Citation: Mn. Saleh et al., PHASE-II TRIAL OF MURINE MONOCLONAL-ANTIBODY D612 COMBINED WITH RECOMBINANT HUMAN MONOCYTE COLONY-STIMULATING FACTOR (RHM-CSF) IN PATIENTS WITH METASTATIC GASTROINTESTINAL CANCER, Cancer research, 55(19), 1995, pp. 4339-4346
PHASE-I CLINICAL AND PHARMACOLOGICAL STUDY OF SUPPRESSION OF HUMAN ANTIMOUSE ANTIBODY-RESPONSE TO MONOCLONAL-ANTIBODY L6 BY DEOXYSPERGUALIN
Authors: DHINGRA K FRITSCHE H MURRAY JL LOBUGLIO AF KHAZAELI MB KELLEY S TEPPER MA GRASELA D BUZDAR A VALERO V BOOSER D WHEALIN H COLLINS TJ PURSLEY JM HORTOBAGYI G
Citation: K. Dhingra et al., PHASE-I CLINICAL AND PHARMACOLOGICAL STUDY OF SUPPRESSION OF HUMAN ANTIMOUSE ANTIBODY-RESPONSE TO MONOCLONAL-ANTIBODY L6 BY DEOXYSPERGUALIN, Cancer research, 55(14), 1995, pp. 3060-3067
CD16(- SPONTANEOUS ELEVATION AND PHARMACOLOGICAL INDUCTION BY RECOMBINANT HUMAN MACROPHAGE-COLONY-STIMULATING FACTOR() MONOCYTES IN PATIENTS WITH CANCER )
Authors: SALEH MN GOLDMAN SJ LOBUGLIO AF BEALL AC SABIO H MCCORD MC MINASIAN L ALPAUGH RK WEINER LM MUNN DH
Citation: Mn. Saleh et al., CD16(- SPONTANEOUS ELEVATION AND PHARMACOLOGICAL INDUCTION BY RECOMBINANT HUMAN MACROPHAGE-COLONY-STIMULATING FACTOR() MONOCYTES IN PATIENTS WITH CANCER ), Blood, 85(10), 1995, pp. 2910-2917
Risultati: 1-25 | 26-39